Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 4:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 32 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Coronary Artery Disease Progression Clear all
Completed Phase 2Phase 3 Interventional

MARS - Monitored Atherosclerosis Regression Study

NCT00116870
View directory record Official record
Conditions
Atherosclerosis, Coronary Artery Disease
Interventions
lovastatin
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
21 Years to 67 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1985 – 1992
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 10, 2009 · Synced Jul 22, 2026, 4:37 PM EDT
Not listed No phase listed Observational

Prediction of Progression of Coronary Artery Disease (CAD) Using Vascular Profiling of Shear Stress and Wall Morphology

NCT01316159
View directory record Official record
Conditions
Coronary Atherosclerosis, Acute Coronary Syndrome, Percutaneous Coronary Intervention, Endothelial Shear Stress, Arterial Remodeling
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 15, 2011 · Synced Jul 22, 2026, 4:37 PM EDT
Completed Phase 4 Interventional Results available

Rivaroxaban Versus Warfarin in the Evaluation of Progression of Coronary Calcium

NCT02376010
View directory record Official record
Conditions
Atherosclerosis
Interventions
rivaroxaban, Warfarin
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years to 84 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2024 · Synced Jul 22, 2026, 4:37 PM EDT
Completed No phase listed Observational

Hepatitis C Treatment and Atherosclerosis

NCT00659256
View directory record Official record
Conditions
Chronic Hepatitis C, Atherosclerosis
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
30 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Jul 22, 2026, 4:37 PM EDT
Completed Phase 4 Interventional

Semaglutide Treatment On Coronary Progression

NCT03985384
View directory record Official record
Conditions
Type 2 Diabetes, Coronary Artery Disease
Interventions
Semaglutide 2 MG/1.5 ML Subcutaneous Solution, Placebo
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
40 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Jul 22, 2026, 4:37 PM EDT
Completed Phase 3 Interventional

STRADIVARIUS (Strategy To Reduce Atherosclerosis Development InVolving Administration of Rimonabant - the Intravascular Ultrasound Study)

NCT00124332
View directory record Official record
Conditions
Coronary Atherosclerosis
Interventions
Rimonabant (SR141716), Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
839 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 19, 2009 · Synced Jul 22, 2026, 4:37 PM EDT
Recruiting Phase 4 Interventional

Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT

NCT05708859
View directory record Official record
Conditions
Type II Diabetes, Atherosclerosis
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Matthew J. Budoff
Other
Eligibility
40 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2024 · Synced Jul 22, 2026, 4:37 PM EDT
Completed Phase 2 Interventional Results available

Effect of SNF472 on Progression of Cardiovascular Calcification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD)

NCT02966028
View directory record Official record
Conditions
Cardiovascular Diseases, Cardiovascular Abnormalities, Calcifications, Vascular, Endstage Renal Disease, ESRD, Coronary Artery Calcification
Interventions
SNF472, Placebo
Drug
Lead sponsor
Sanifit Therapeutics S. A.
Other
Eligibility
18 Years to 80 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
46
States / cities
Bakersfield, California • Chula Vista, California • Escondido, California + 42 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced Jul 22, 2026, 4:37 PM EDT
Completed Phase 3 Interventional Results available

Efficacy Study of Pioglitazone Compared to Glimepiride on Coronary Atherosclerotic Disease Progression in Subjects With Type 2 Diabetes Mellitus

NCT00225277
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Pioglitazone, Glimepiride
Drug
Lead sponsor
Takeda
Industry
Eligibility
35 Years to 85 Years
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
65
States / cities
Birmingham, Alabama • Phoenix, Arizona • Huntington Beach, California + 62 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2012 · Synced Jul 22, 2026, 4:37 PM EDT
Withdrawn Not applicable Interventional

Effects of Zortress® + Tacrolimus vs. Standard Immunosuppression on Progression of Coronary Artery Calcifications and Bone Disease in de Novo Renal Transplant Recipients

NCT01612299
View directory record Official record
Conditions
Renal Transplant
Interventions
Zortress® /Everolimus
Drug
Lead sponsor
University of Kentucky
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 6, 2017 · Synced Jul 22, 2026, 4:37 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Kronos Early Estrogen Prevention Study (KEEPS)

NCT00154180
View directory record Official record
Conditions
Menopause, Arteriosclerosis
Interventions
Conjugated equine estrogens 0.45 mg/day, Transdermal estradiol, 50 mcg/day, Micronized progesterone, 200 mg/day x 12 d/month, CEE , progesterone, estradiol patch or placebo for each, CEE, progesterone, transdermal patch or the placebo
Drug
Lead sponsor
Kronos Longevity Research Institute
Other
Eligibility
42 Years to 58 Years · Female only
Enrollment
728 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2012
U.S. locations
9
States / cities
Phoenix, Arizona • San Francisco, California • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2009 · Synced Jul 22, 2026, 4:37 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease

NCT00655473
View directory record Official record
Conditions
Coronary Heart Disease
Interventions
Dalcetrapib (RO4607381), Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
11
States / cities
Jacksonville, Florida • Royal Oak, Michigan • Minneapolis, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2020 · Synced Jul 22, 2026, 4:37 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Doxycycline Treatment to Prevent Progressive Coronary Artery Dilation in Children With Kawasaki Disease

NCT01917721
View directory record Official record
Conditions
Kawasaki Disease, Coronary Aneurysm
Interventions
Doxycycline, Placebo
Drug
Lead sponsor
Hawaii Pacific Health
Other
Eligibility
1 Month to 21 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Jul 22, 2026, 4:37 PM EDT
Completed Phase 3 Interventional Results available

Rosiglitazone Versus a Sulfonylurea On Progression Of Atherosclerosis In Patients With Heart Disease And Type 2 Diabetes

NCT00116831
View directory record Official record
Conditions
Atherosclerosis
Interventions
Glipizide, rosiglitazone maleate
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 80 Years
Enrollment
672 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
39
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Jul 22, 2026, 4:37 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Testosterone Replacement in Older Men and Atherosclerosis Progression

NCT00287586
View directory record Official record
Conditions
Hypogonadism, Atherosclerosis
Interventions
Testosterone Gel (Androgel), Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
60 Years and older · Male only
Enrollment
308 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2012
U.S. locations
3
States / cities
Phoenix, Arizona • Los Angeles, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Jul 22, 2026, 4:37 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Natural History of Carotid Plaque as Determined by 3D Ultrasound

NCT03314818
View directory record Official record
Conditions
Atherosclerotic Disease, Plaque, Atherosclerotic, Heart Diseases, Stroke, Cardiovascular Risk Factor
Interventions
Ultrasound 3D Imaging
Device
Lead sponsor
Pieter Muntendam
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Lauderhill, Florida
Source: ClinicalTrials.gov public record
Updated Oct 18, 2017 · Synced Jul 22, 2026, 4:37 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Aliskiren Effect on Aortic Plaque Progression

NCT01417104
View directory record Official record
Conditions
Atherosclerosis
Interventions
Aliskiren, Placebo
Drug
Lead sponsor
Ohio State University
Other
Eligibility
45 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Jul 22, 2026, 4:37 PM EDT
Completed Not applicable Interventional

Effects of Lowering Dialysate Calcium Level on Progression of Coronary Artery Calcification and Bone Histomorphometry

NCT00297219
View directory record Official record
Conditions
End-Stage Renal Disease, Hemodialysis
Interventions
Low dialysate calcium, high dialysate calcium
Drug
Lead sponsor
Ege University
Other
Eligibility
18 Years to 80 Years
Enrollment
457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 3, 2009 · Synced Jul 22, 2026, 4:37 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Antiretrovirals and Rate of Progression in Carotid Artery Intima-medial Thickness in HIV

NCT00575939
View directory record Official record
Conditions
HIV Infections, Atherosclerosis
Interventions
Not listed
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 18, 2014 · Synced Jul 22, 2026, 4:37 PM EDT
Active, not recruiting Phase 3 Interventional

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

NCT06383390
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
Interventions
Retatrutide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
205
States / cities
Alabaster, Alabama • Birmingham, Alabama • Daphne, Alabama + 158 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 22, 2026, 4:37 PM EDT
Active, not recruiting Phase 3 Interventional

Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events

NCT05360446
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Inclisiran sodium 300 mg, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
609 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
27
States / cities
Huntsville, Alabama • Anchorage, Alaska • Beverly Hills, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Jul 22, 2026, 4:37 PM EDT
Withdrawn Not applicable Interventional

Awake Axillary Impella 5.5 Placement - A Feasibility Trial

NCT05782491
View directory record Official record
Conditions
Cardiogenic Shock
Interventions
Interscalene Block, PECS II Block, Superficial Cervical Plexus Block
Procedure
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 18, 2024 · Synced Jul 22, 2026, 4:37 PM EDT
Completed Phase 4 Interventional

Effect of Colchicine on Progression of Known Coronary Atherosclerosis in Patients With Stable Coronary Artery Disease

NCT06342609
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Colchicine 0.5 MG
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
30 Years to 85 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2024 · Synced Jul 22, 2026, 4:37 PM EDT
Completed Phase 3 Interventional Results available

Firefighter Aged Garlic Extract Investigation With CoQ10 as a Treatment for Heart Disease (FAITH)

NCT00860847
View directory record Official record
Conditions
Coronary Atherosclerosis, Coronary Artery Calcification, Coronary Stenosis
Interventions
Aged garlic extract and Coenzyme Q10
Dietary Supplement
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
35 Years to 84 Years · Male only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Mar 11, 2015 · Synced Jul 22, 2026, 4:37 PM EDT